Myocardial Pacing Lead
Medtronic, Inc. · Decision date Feb 20, 2026
What did the FDA decide?
FDA records P120017/S039 as a supplement to PMA P120017, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 20, 2026.
FDA approval order statement
an update to the part cleaning process at supplier
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 20, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P120017/S039
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- DTB
- Decision code
- OK30
- Decision date
- Feb 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: permanent pacemaker Electrode.
- Applicant
- Medtronic, Inc.
- Product code
- DTB
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P120017/S039 received
Application receipt date recorded by FDA.
P120017/S039 · FDA decision
30-Day Notice
P120017/S040 · Related supplement
Myocardial Pacing Lead
Timeline entries are records held by MedtechLedger for P120017. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120017
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Myocardial Pacing LeadP120017/S040 | Medtronic, Inc. | PMA supplement | Apr 15, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P120017/S039
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records